Endo International to manufacture Novavax’s candidate COVID-19 vaccine

Novavax Inc. (NASDAQ: NVAX) said that Endo International (NASDAQ: ENDP) will be in charge of manufacturing its COVID-19 vaccine after the two companies inked a non-exclusive agreement on Friday. Earlier this year in July, the U.S. government invested £1.27 billion in Novavax under its “Operation Warp Speed” program. In a separate statement, Endo said that its subsidiary, Par Sterile, has dedicated a manufacturing facility in Rochester for the production of Novavax COVID-19 vaccine. Financial and related terms of the deal were not disclosed at this stage. Endo closed the regular session about 1.5% down on Friday. The Dublin-based pharmaceutical company